MM&M’s Pipeline 2010 draws from the best in drug development, profiling 15 agents with the highest approval probability and brightest commercial prospects. These are the prime near-term launch candidates. The report also provides updates on 202 products in a host of therapeutic areas. Marc Iskowitz reports
The healthcare reform legislation inching toward the president’s desk will mean big changes for the pharmaceutical industry, whatever its final form. Matthew Arnold takes a look at what’s ahead
MM&M Awards 2009: Tickled Pink
November 13, 2009
11:38 pm
Healthcare marketing and communications execs, and pharma manufacturers, flocked to the sixth annual MM&M Awards gala presentation at New York City’s Tavern on the Green on October 29.
Musculoskeletal journal launches
November 13, 2009
11:26 pm
Sage launched Therapeutic Advances in Musculoskeletal Disease, the seventh title in its Therapeutic Advances series.
Elsevier unveils MD Consult mobile
November 13, 2009
11:23 pm
To reach docs that may not have a laptop at the ready when medical information is needed, Elsevier optimized its MD Consult service for BlackBerrys, iPhones and smartphones.
Companies to build sales force around lupus drug launch
Human Genome Sciences and GlaxoSmithKline are planning the launch of lupus drug Benlysta, and step one involves building a sales force to call on rheumatologists.
Instead of merely slashing reps to trim costs, GlaxoSmithKline is relocating the positions, said CEO Andrew Witty.
Regulatory changes key: Hamburg
November 13, 2009
11:08 pm
FDA commissioner Margaret Hamburg says it is important for the nation to strengthen its commitment to regulatory science so that it becomes a robust and respected discipline in the broader scientific enterprise.
Sen. Grassley questions advocacy group funding
November 13, 2009
11:05 pm
The ranking member of the Senate Finance Committee, Sen. Charles Grassley (R-IA) has asked state-level chapters of the National Alliance on Mental Illness (NAMI) to account for funds given directly to them by drug companies or coming to them through drug company funding of the organization.